Advertisement
Document › Details
GSK plc. (6/6/24). "Press Release: GSK Accelerates Oligonucleotide Platform and Pipeline Medicines with Acquisition of Elsie Biotechnologies [For media and investors only]". London.
Organisation | GSK plc (LSE: GSK, NYSE: GSK) | |
Group | GSK (Group) | |
Organisation 2 | Elsie Biotechnologies (US) | |
Group | GSK (Group) | |
Product | oligonucleotide drug | |
Product 2 | oligonucleotide technology | |
Index term | Elsie Biotechnologies–GSK: investment, 202406 acquisition of Elsie Biotechnologies for up to $50m by GSK | |
Index term 2 | GSK–Elsie Biotechnologies: oligonucleotide technology, 202307– collab advancing oligo discovery technology | |
Person | Wood, Tony (GSK 202210 CSO) | |
Person 2 | Green, Kevin (Elsie Biotechnologies 202406 COO) | |
For media and investors only
> Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
> Elsie’s platform technology will expand GSK’s broad oligonucleotide pipeline
GSK plc (LSE/NYSE: GSK) today announced that it has acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million).
Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.
This acquisition allows GSK to integrate Elsie’s oligonucleotide discovery, synthesis, and delivery technologies to enhance GSK’s platform R&D capabilities. This follows a successful research collaboration with Elsie, announced in July 2023, in which GSK was able to explore and validate the technology.
Tony Wood, Chief Scientific Officer, GSK, said: “We have already made great strides in oligonucleotide drug development through our work in chronic hepatitis B and steatotic liver disease, and are thrilled to work alongside the talented team at Elsie to accelerate a next-generation oligonucleotide platform. By bringing together Elsie’s expertise and our internal capabilities, we can design and develop oligonucleotides for difficult-to-treat diseases of scale with larger patient populations.”
Data generated with the Elsie platform, combined with GSK’s expertise in the use of artificial intelligence and machine learning, will support the development of predictive models for future oligonucleotide design.
Kevin Green, Chief Operating Officer, Elsie, said: “We are thrilled to be a part of GSK and work alongside the talented R&D team dedicated to oligonucleotide drug development. We believe our platform will make significant contributions to the field and we believe GSK is the best partner to help advance this effort.”
The acquisition is aligned to GSK’s approach of uniting Science and Technology, including advancing novel platform technologies, to accelerate drug development and ultimately deliver innovative medicines to patients, better and faster. Currently GSK is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
This agreement is not subject to closing conditions and the acquisition has been completed.
About Elsie Biotechnologies
Elsie is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics by integrating discovery, development, and delivery to potentially increase potency, decrease toxicity, and optimise delivery.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q1 Results for 2024.
Record changed: 2024-07-26 |
Advertisement
More documents for GSK (Group)
- [1] CureVac N.V.. (7/3/24). "Press Release: GSK and CureVac to Restructure Collaboration into New Licensing Agreement". London, Tübingen & Boston, MA....
- [2] CureVac N.V.. (5/28/24). "Press Release: CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK". Tübingen & Boston, MA....
- [3] BioVersys AG. (5/7/24). "Press Release: BioVersys Announces Expansion of Strategic Collaboration with GSK and Extension of its Series C Round by CHF 12.3 Million". Basel....
- [4] GSK plc. (1/9/24). "Press Release: GSK Enters Agreement to Acquire Aiolos Bio"....
- [5] Forbion Capital Partners. (1/9/24). "Press Release: Forbion Portfolio Company Aiolos Bio, Inc. (Aiolos) to Be Acquired by GSK for up to $1.4 Billion"....
- [6] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
- [7] GSK plc. (12/20/23). "Press Release: GSK Enters Exclusive License Agreement with Hansoh for HS-20093". London....
- [8] Aiolos Bio, Inc.. (10/24/23). "Press Release: Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody". San Francisco, CA & London....
- [9] GSK plc. (10/20/23). "Press Release: GSK Enters Exclusive License Agreement with Hansoh for HS-20089". London....
- [10] LimmaTech Biologics AG. (7/20/23). "Press Release: GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine". Schlieren....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top